Manufacturing

We believe our large scale capacity manufacturing sites in India provide us with cost advantages in terms of wages and raw materials prices as compared to many of our global competitors, as well as economies of scale.

In addition, by virtue of our integrated operations, we believe that we enjoy competitive advantages in the form of cost efficiencies by producing across the value chain, thereby reducing our dependence on third parties for supply of starting materials and helps to insulate us from significant volatility in raw materials prices.

The APIs from our manufacturing facilities are used for solid dosage formulations under our generics business. Such integration between our solid dosage formulations and API business lines, allows us to continuously improve our cost of production. Multiple products in our Radiopharmaceuticals and Allergy Therapy Products business lines are manufactured in our CMO facilities.

Additionally, our radiopharmaceutical products are distributed through more than 50 radiopharmacies.

We operate our plants in accordance with cGMP and/or other applicable requirements. We currently operate four US FDA approved manufacturing facilities in North America and two US FDA approved manufacturing facilities in India.

As at June 30, 2018, we employed over 700 quality employees, over 60 regulatory affairs employees and over 50 technical services employees to support our production of quality products.

Manufacturing Facilities

North America

  • Kirkland, Montreal, Canada

  • Spokane, Washington, USA

  • Salisbury, Maryland, USA

  •  

India

  • Nanjangud, Karnataka, India

  • Roorkee, Uttarakhand, India